272 related articles for article (PubMed ID: 16978274)
1. Mass screening for prostate cancer in patients with end-stage renal disease: a comparative study.
Wada Y; Nakanishi J; Takahashi W; Kai N; Nakayama Y; Yamashita Y; Honda J; Ueda S
BJU Int; 2006 Oct; 98(4):794-7. PubMed ID: 16978274
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of prostate cancer in end-stage renal disease patients.
Kamata T; Fushimi K
Urol Int; 2008; 80(4):419-24. PubMed ID: 18587254
[TBL] [Abstract][Full Text] [Related]
3. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer screening with prostate-specific antigen in hemodialysis patients.
Horinaga M; Kitamura K; Saito S; Ukimura O; Nakanoma T; Okihara K; Kitagawa M; Nakanishi H; Miki T
Urol Int; 2007; 78(4):334-7. PubMed ID: 17495492
[TBL] [Abstract][Full Text] [Related]
5. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
6. [Characteristics of screening-detected prostate cancer on health checkup].
Uchida K; Akaza H
Gan To Kagaku Ryoho; 1998 Aug; 25(10):1527-32. PubMed ID: 9725044
[TBL] [Abstract][Full Text] [Related]
7. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
8. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR
Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
[TBL] [Abstract][Full Text] [Related]
9. Mass screening of 12,027 elderly men for prostate carcinoma by measuring serum prostate specific antigen.
Zhang HF; Wang HL; Xu N; Li SW; Ji GY; Li XM; Pan YZ; Zhang L; Zhao XJ; Gao HW
Chin Med J (Engl); 2004 Jan; 117(1):67-70. PubMed ID: 14733776
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
[TBL] [Abstract][Full Text] [Related]
11. Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan.
Okihara K; Kitamura K; Okada K; Mikami K; Ukimura O; Miki T
Int J Urol; 2008 Feb; 15(2):156-60; discussion 161. PubMed ID: 18269453
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer detection in men with a 'normal' total prostate-specific antigen (PSA) level using percentage free PSA: a prospective screening study.
Rowe EW; Laniado ME; Walker MM; Patel A
BJU Int; 2005 Jun; 95(9):1249-52. PubMed ID: 15892810
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
[TBL] [Abstract][Full Text] [Related]
14. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
15. Identification of clinically significant prostate cancer by prostate-specific antigen screening.
Smith RP; Malkowicz SB; Whittington R; VanArsdalen K; Tochner Z; Wein AJ
Arch Intern Med; 2004 Jun; 164(11):1227-30. PubMed ID: 15197049
[TBL] [Abstract][Full Text] [Related]
16. [Five-year results of prostate specific antigen (PSA) screening in Yokosuka City--comparative study between PSA-screened group and non-screened group].
Noguchi S; Satomi Y; Sakai N; Takemura H; Ikeda S; Okui N; Kobayashi M; Fukuoka H; Furuhata A
Hinyokika Kiyo; 2008 Mar; 54(3):197-201. PubMed ID: 18411775
[TBL] [Abstract][Full Text] [Related]
17. Changes in baseline PSA levels in Japanese men from 1988 to 2003.
Ohi M; Ito K; Yamamoto T; Miyakubo M; Takechi H; Kubota Y; Suzuki K
Urology; 2008 Jul; 72(1):95-8. PubMed ID: 18455775
[TBL] [Abstract][Full Text] [Related]
18. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.
Berger AP; Deibl M; Strasak A; Bektic J; Pelzer AE; Klocker H; Steiner H; Fritsche G; Bartsch G; Horninger W
Urology; 2007 Jan; 69(1):134-8. PubMed ID: 17270635
[TBL] [Abstract][Full Text] [Related]
19. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project.
Pelzer AE; Tewari A; Bektic J; Berger AP; Frauscher F; Bartsch G; Horninger W
Urology; 2005 Nov; 66(5):1029-33. PubMed ID: 16286118
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan.
Takechi H; Ito K; Yamamoto T; Miyakubo M; Ohi M; Suzuki K
Urology; 2008 Nov; 72(5):1111-5. PubMed ID: 18342926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
